A Study of S-892216 in Participants With COVID-19

• Status: COMPLETED
• Trial end date: 2025-09-22

Summary

The primary objective of this study is to investigate the antiviral effect of S-892216 in participants with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

• Phase: PHASE2

Details

• Lead Sponsor: Shionogi